Olanzapina Ratiopharm (Olanzapine)

Olanzapina Ratiopharm is an atypical antipsychotic used in the management of major psychiatric disorders.

• Schizophrenia: reduces positive and negative symptoms and helps prevent relapse.
• Bipolar I disorder (manic episodes): stabilises mood and decreases the frequency of manic episodes.
• Bipolar I disorder (depressive episodes): alleviates depressive symptoms when used as part of combination therapy.
• Schizoaffective disorder: improves overall psychotic symptom control.
• Maintenance therapy: supports long‑term symptom control after acute stabilization.

• Olanzapine exerts its antipsychotic effect primarily by antagonising dopamine D2 receptors and serotonin 5‑HT2A receptors in the central nervous system. This combined blockade modulates dopaminergic and serotonergic neurotransmission, which is thought to reduce psychotic symptoms and stabilise mood. Additional affinity for histamine, muscarinic and adrenergic receptors contributes to its broader pharmacologic profile.

Olanzapina Ratiopharm may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Weight gain: increased appetite and caloric intake.
• Sedation: drowsiness or feeling of being slowed down.
• Dry mouth: reduced salivary flow.
• Constipation: decreased bowel motility.
• Orthostatic hypotension: light‑headedness upon standing.
• Elevated prolactin: menstrual irregularities or galactorrhoea.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
• Tardive dyskinesia: involuntary, repetitive movements, often of the face.
• Severe hyperglycaemia or new‑onset diabetes mellitus.
• Agranulocytosis: markedly reduced white‑blood cell count.
• Myocardial infarction or other serious cardiac events.
• Seizures: especially in patients with a history of epilepsy.

Olanzapina Ratiopharm requires careful monitoring and patient education before and during treatment.

• Cardiovascular monitoring: assess blood pressure and heart rate regularly.
• Metabolic monitoring: track weight, fasting glucose, and lipid profile.
• CNS effects: advise patients about sedation and avoid operating heavy machinery.
• Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed.
• Drug‑specific contraindications: avoid in patients with known hypersensitivity to olanzapine.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olanzapina Ratiopharm can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels.
• CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.
• Anticholinergic agents: heightened risk of anticholinergic toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce olanzapine concentrations.
• Antidiabetic drugs: olanzapine‑induced hyperglycaemia may require dose adjustments.
• Antihypertensives: orthostatic hypotension may be enhanced.
• Lithium: increased risk of neurotoxicity.
• Smoking: may lower olanzapine levels; monitor clinical response.